Develops potential cancer medicines, including immune-stimulating drugs and drugs that target DNA repair, for patients with cancer.
10-K, filed Mar 30, 2026We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing, innovative…View ↗
Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to…View ↗
EIK1003 and EIK1004 are selective PARP1 inhibitors. These product candidates are designed to inhibit PARP1 while sparing PARP2, thereby…View ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
−$86.1MView ↗
Competes with Inimmune, AstraZeneca, Hengrui, Hansoh Pharma, Gilead, Nerviano, Synnovation Therapeutics, Kainos, Duke Street Bio, Acerand Therapeutics, Shenzhen Yangli, Vividion, IDEAYA, Nimbus Therapeutics, and MOMA Therapeutics
10-K, filed Mar 30, 2026We are developing EIK1001, a TLR 7/8 dual-agonist. We are aware of a number of competing product candidates targeting TLR 7/8 in the…View ↗
Loading...